Delayed COVID-19 rebound following nirmatrelvir/ritonavir treatment in B-cell-depleted patients

Int J Rheum Dis. 2023 Feb;26(2):396-397. doi: 10.1111/1756-185X.14493. Epub 2022 Nov 15.

Authors

Louisa Schminke¹, Martin Fleck^{1

2}

Affiliations

¹ Department of Rheumatology/Clinical Immunology, Asklepios Medical Center Bad Abbach, Bad Abbach, Germany.
² Department of Internal Medicine I, Rheumatology/Clinical Immunology, University Hospital Regensburg, Regensburg, Germany.

PMID: 36378101
DOI: 10.1111/1756-185X.14493

No abstract available

MeSH terms

COVID-19 Drug Treatment
COVID-19*
Humans
Ritonavir / adverse effects

Substances

nirmatrelvir
Ritonavir

Supplementary concepts

COVID-19 rebound